Checkmate Pharmaceuticals, Inc. (CMPI) |
|
10.5 0 (0%)
|
12-31 19:00 |
|
Open: |
10.49 |
Pre. Close: |
10.5 |
|
High:
|
10.5 |
Low:
|
10.49 |
|
Volume:
|
63,651 |
Market Cap:
|
0(M) |
|
|
|
Technical analysis |
as of: 2022-11-18 4:19:32 PM |
|
Short-term rate:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
|
| Target: |
Six months: 12.26 One year: 14.32 |
| Support: |
Support1: 10.49 Support2: 10.48 |
| Resistance: |
Resistance1: 10.5 Resistance2: 12.26 |
| Pivot: |
10.5 |
| Moving Average: |
MA(5): 10.5 MA(20): 10.5
MA(100): 10.5 MA(250): 7.51  |
| MACD: |
MACD(12,26): 0  Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 100 %D(3): 100 |
| RSI: |
RSI(14): 88.8 |
| 52-week: |
High: 10.5 Low: 2 |
| Average Vol(K): |
3-Month: 64 (K) 10-Days: 64 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CMPI ] has closed Bollinger Bands are 0% narrower than normal. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
10.51 - 10.56 |
10.56 - 10.6 |
|
Low:
|
10.37 - 10.43 |
10.43 - 10.48 |
|
Close:
|
10.41 - 10.5 |
10.5 - 10.58 |
|
Company Description |
|
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc. |
Headline News |
Thu, 12 May 2022
Checkmate Pharmaceuticals Announces First Quarter 2022 ... - GlobeNewswire
Sun, 24 Apr 2022
U.S stock market gainers for the week - Nairametrics
Fri, 22 Apr 2022
StockWatch: Checkmate Shares Quadruple on Regeneron Buyout - Genetic Engineering & Biotechnology News
Tue, 19 Apr 2022
Regeneron To Acquire Checkmate Pharmaceuticals and Its ... - Goodwin Procter
Tue, 29 Mar 2022
Checkmate Pharmaceuticals Announces Full Year 2021 Financial ... - GlobeNewswire
Wed, 09 Feb 2022
Checkmate Pharmaceuticals Appoints Alan Bash as President and ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
22 (M) |
| Shares Float |
7 (M) |
|
% Held by Insiders
|
4.6 (%) |
|
% Held by Institutions
|
77.5 (%) |
|
Shares Short
|
79 (K) |
|
Shares Short P.Month
|
42 (K) |
Stock Financials |
|
EPS
|
-2.93 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.53 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-42.4 |
|
Return on Equity (ttm)
|
-75.5 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-50 (M) |
|
Levered Free Cash Flow
|
-24 (M) |
Stock Valuations |
|
PE Ratio
|
-3.6 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
4.13 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-4.63 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
